| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $37.7M | 0.05% | 394.41K | −11% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a IRMD trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 2, 2026 | Allen Monty KDirector | Sale at price 86.35 - 86.44 per share. | 1.4K | $122.62K |
| Jun 17, 2026 | Glenn John FChief Financial Officer | — | 5.8K | — |
| Jun 3, 2026 | Scharen-Guivel Hilda FrederiqueDirector | Sale at price 95.00 per share. | 3K | $285.00K |
| May 31, 2026 | Susi Roger EChief Executive Officer | Sale at price 88.68 - 91.91 per share. | 2.5K | $226.51K |
| May 26, 2026 | Susi Roger EChief Executive Officer | Sale at price 91.81 - 92.93 per share. | 7.5K | $691.04K |
| May 18, 2026 | Susi Roger EChief Executive Officer | Sale at price 85.95 - 88.65 per share. | 7.5K | $657.26K |
| May 11, 2026 | Susi Roger EChief Executive Officer | Sale at price 83.70 - 85.90 per share. | 7.5K | $631.34K |
| May 4, 2026 | Susi Roger EChief Executive Officer | Sale at price 83.78 - 87.31 per share. | 7.5K | $642.86K |
| Apr 27, 2026 | Susi Roger EChief Executive Officer | Sale at price 84.13 - 89.70 per share. | 7.5K | $657.71K |
| Apr 20, 2026 | Susi Roger EChief Executive Officer | Sale at price 89.73 - 93.90 per share. | 7.5K | $694.12K |
| Apr 13, 2026 | Susi Roger EChief Executive Officer | Sale at price 91.84 - 94.55 per share. | 7.5K | $697.19K |
| Apr 6, 2026 | Susi Roger EChief Executive Officer | Sale at price 94.36 - 96.78 per share. | 7.5K | $717.21K |
| Mar 29, 2026 | Susi Roger EChief Executive Officer | Sale at price 94.81 - 96.53 per share. | 7.5K | $712.61K |
| Mar 23, 2026 | Susi Roger EChief Executive Officer | Sale at price 99.58 - 102.02 per share. | 7.5K | $752.61K |
| Mar 16, 2026 | Susi Roger EChief Executive Officer | Sale at price 101.18 - 102.43 per share. | 7.5K | $762.97K |
| Mar 9, 2026 | Susi Roger EChief Executive Officer | Sale at price 100.04 - 100.11 per share. | 7.5K | $750.48K |
| Mar 5, 2026 | Susi Roger EChief Executive Officer | Sale at price 98.25 - 99.12 per share. | 7.5K | $737.92K |
| Feb 12, 2026 | Allen Monty KDirector | Sale at price 100.26 per share. | 1K | $100.26K |
| Jan 25, 2026 | Susi Roger EChief Executive Officer | Sale at price 100.54 - 101.38 per share. | 5K | $503.25K |
| Jan 19, 2026 | Susi Roger EChief Executive Officer | Sale at price 101.03 - 102.70 per share. | 5K | $509.23K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 0.6 | 5.8 | -7.0 | -13.3 | 8.7 | 5.4 | -4.9 | -4.9 | -0.2 | 4.4 | −7.5% | ||
| 2025 | 7.7 | -9.0 | -2.7 | -0.1 | 10.4 | 3.3 | -2.4 | 24.2 | -1.8 | 7.9 | 21.4 | 4.4 | +76.9% |
| 2024 | -12.8 | 1.4 | 4.8 | -7.7 | 4.6 | 3.5 | 6.3 | 0.5 | 7.1 | -2.0 | 9.5 | 2.0 | +15.9% |
| 2023 | 32.2 | 1.5 | 3.7 | 5.8 | 13.0 | 1.5 | -8.0 | 5.2 | -4.0 | -8.2 | 7.9 | 8.0 | +67.8% |
| 2022 | -13.8 | 24.8 | -9.8 | -26.6 | -0.7 | 3.8 | 24.5 | -20.6 | -10.4 | -3.4 | 1.8 | -4.3 | −38.8% |
| 2021 | 8.5 | -9.9 | 15.6 | 7.5 | 0.4 | 5.8 | 14.5 | 0.3 | -0.5 | 11.1 | 20.6 | 2.7 | +102.7% |
| 2020 | 9.1 | -6.9 | -10.1 | 1.9 | 6.8 | -0.2 | -4.0 | -4.8 | 0.8 | 5.9 | 8.2 | -7.0 | −2.5% |
| 2019 | 12.1 | -8.8 | 12.4 | -11.0 | -16.6 | -2.0 | 16.8 | -19.7 | 9.6 | 20.1 | -13.0 | 6.4 | −4.4% |
| 2018 | -2.0 | -12.5 | 10.8 | 21.2 | 6.3 | 11.9 | 10.8 | 19.6 | 35.1 | -32.8 | 15.3 | -15.0 | +61.5% |
| 2017 | -17.6 | -8.7 | 6.6 | -3.4 | -5.2 | 5.5 | 14.5 | 2.5 | -5.0 | 48.4 | -2.1 | 8.6 | +36.5% |
| 2016 | -30.6 | -8.3 | 7.5 | -14.6 | 13.3 | 17.4 | -11.0 | -3.6 | -9.0 | -44.4 | 16.9 | 0.5 | −60.4% |
| 2015 | 13.5 | -1.0 | 5.0 | 6.4 | 19.1 | 20.6 | 6.6 | -3.6 | 1.9 | 8.8 | 17.0 | -9.6 | +117.3% |
| 2014 | 18.3 | -35.1 | 3.7 | 21.3 | 46.3 | +41.3% |
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories. The company offers MRidium 3870 and 3860+ MRI Compatible IV Infusion Pump System with associated disposable IV tubing sets; 3880 MRI compatible patient vital signs monitoring system; and 3600 FMD1 with remote alarm logging unit ferromagnetic detection device. It also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. The company serves hospitals, acute care facilities, and outpatient imaging centers. It sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors in the United States and internationally. The company was incorporated in 1992 and is headquartered in Orlando, Florida.
Buy / hold / sell counts